COVID-19 Update

COVID-19 has imposed an unsettling situation upon our community and our business, but at Cleveland Diabetes Care and our affiliates, KRS and Complete, we are committed to fighting back the best way we know how. By providing better medicine for better lives we will continue operations that include creation and distribution of life saving medications and testing kits to all reaches of our great nation.

Diabetes Care Worldwide

Targeting a range of unmet needs
in diabetes

Specialized in the next generation
of diabetes pharmaceuticals

Our science

Photo of our doctors

Cleveland Diabetes Care is focused on the field of diabetes, endocrinology and metabolism.

We specialize on Endocrinology and Metabolism systems within the Diabetes disease pharmaceutical market. Diabetes is a medical subspecialty devoted to understanding liver, pancreas, kidneys, and perceptual symptoms resulting from circuit-specific endocrinology and metabolism dysfunction and includes a range of serious diseases and conditions.

Photo of our doctors

The Cleveland Diabetes Care pipeline will initially target the treatment of diabetes, endocrinology, and metabolic diseases.

Diabetes affects millions of people around the world. Currently available treatment options for these conditions are known to have significant limitations that can result in high rates of therapy discontinuation and unsatisfactory efficacy and safety profiles.

About our company

We are a clinical-stage biopharmaceutical and medical device company aimed at the development and commercialization of a portfolio of product candidates to treat patients suffering from diabetes.

Leveraging our domain expertise, we have acquired or licensed four (4) development stage proprietary compounds and four (4) medical devices that we believe have innovative mechanisms of action with potentially positive therapeutic outcomes.

We plan to develop and - if approved by the applicable regulatory authorities - commercialize our products for the diabetes pharmaceutical market, which represented a $471 billion worldwide market in 2019.